Community
Products
Complications & Care
Food
Columns
Medications
Research
Fitness
Monitoring
Psychology
Health Care
Legal
Celebrities
Pregnancy
About Us
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT

Discuss this Topic in the Forum

See What's Inside…

See the entire table of contents here!

View Diabetes Health Magazine For Free Online

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

Free Subscription to Diabetes Health Professional

If you are a physician, educator and medical professional who focus on the treatment of diabetes, then this is the must have resource for you.

Finally! A fresh take on the “professional” journal. Each bi-monthly issue cuts through the jargon and presents the most important information you need to enhance your practice and assist your patients.

Each bi-monthly issue of Diabetes Health Professional is a self-contained handbook covering products, educational resources and the latest diabetes research, complimented by balanced editorial focused on medical news, drug prescription information, clinical practice recommendations and changing treatment options.

Each quarter we send you the latest, most updated research guides, product guides and educational resource guides available for you and your patients.

Learn More About the Professional Subscription

ADVERTISEMENT
Diabetes Health E-Newsletter

Each week the Diabetes Health E-Newsletter delivers links to the very latest in news, reviews, blogs and videos from Diabetes Health direct to your inbox.

See an example E-Newsletter

As a subscriber you'll get access to the amazing Diabetes Health Digital Advantage™ so you can read the current issue of Diabetes Health magazine online wherever you are!

Email Address:
Area of Interest:
How To Change Your Newsletter Email…

You can cancel your newsletter subscription at anytime by clicking "Unsubscribe" on the bottom of any newsletter you receive

Then enter your new email address in the above form and click "Subscribe"

ADVERTISEMENT
Forums
DHTV
Popular
Top Rated
Byetta Archives
ADVERTISEMENT

Diabetes and Byetta

Updated 2 weeks ago
Amylin Hopes to Begin U.S. Sales of Long-Acting Byetta Early This Year

Amylin Pharmaceuticals has announced that it expects to begin selling a once-weekly version of its diabetes drug, Byetta, by the end of the year. The company reports that the FDA is nearing final inspections of its manufacturing plant and could give the go-ahead for U.S. sales in early March.

comments 2 comments - Mar 4, 2010 - * * * * *

Liraglutide Tested on African Americans with Type 2 Diabetes

Most clinical studies of new drugs are conducted primarily on white men, whether or not they are most affected by the disease the drug is intended to treat.  African Americans, for example, are 1.6 times more likely to have diabetes than non-Hispanic whites.  Why should we assume that what works for white males will also be effective for African Americans, Hispanics, Asians, or, for that matter, women?

comments 0 comments - Aug 6, 2009 - * * * * *

Survey Says Most Endocrinologists and Physicians See a Need for More Byetta and Januvia-Type Drugs

High percentages of endocrinologists, primary care physicians, and managed care organizations surveyed by a research firm say they would like to see additional GLP-1 analogues like Amylin/Eli Lilly's Byetta® and DPP-IV inhibitors like Merck's Januvia® available to treat type 2 diabetes.

comments 6 comments - Jul 25, 2009 - * * * * *

Research Disputes FDA Claim that Exenatide Increase Risk of Acute Pancreatitis

In 2008, the U.S. Food and Drug Administration published strong warnings that the type 2 diabetes drug exenatide (trade name Byetta) might increase risk of acute pancreatitis, a painful inflammation of the pancreas. The FDA's action came in the wake of reports that 30 exenatide users had come down with pancreatitis and that six of them had died from the condition.

comments 1 comment - Jun 19, 2009 - * * * * *

Amylin Cuts Workforce, Asks FDA to Approve Once-Weekly Byetta

It has been an interesting month for San Diego-based Amylin Pharmaceuticals Inc., the co-manufacturer of Byetta (exenatide) with Eli Lilly & Co., and Alkermes Inc. First, the company announced that it will reduce its sales force by 35 percent-200 employees-in hope of saving $20 million this year and $45 million annually starting in 2010. The company plans to retain 325 representatives to sell its diabetes products to doctors and endocrinologists. At the same time, Amylin has petitioned the FDA to approve the marketing of Byetta LAR, a form of the type 2 drug that requires injection only once a week.

comments 1 comment - May 11, 2009 - * * * * *

Type 2 Drugs: EU Approves “Victoza,” FDA Extends Review of “Onglyza”

The European Union's drug regulation agency has recommended that the EU approve the marketing of "Victoza" (liraglutide), a type 2 drug developed by Novo Nordisk.

comments 2 comments - May 6, 2009 - * * * * *

Long-Acting Byetta Tops Two Other Diabetes Drugs in Direct Comparison

Results from DURATION-2, a 26-week test comparing the diabetic drugs Januvia, Actos, and experimental long-acting Byetta (Byetta LAR) show that Byetta produced lower A1c's and more weight loss than the other two drugs.

comments 5 comments - Apr 15, 2009 - * * * * *

Altea Partners With Amylin and Lilly to Develop 12-Hour Byetta Skin Patch

Buoyed by its recent successful phase 1 human clinical trial of a patch that delivers basal insulin through the skin, Atlanta-based Altea Therapeutics says it will work with Eli Lilly and Company and Amylin Pharmaceuticals, Inc., to develop a daily transdermal patch that deliver sustained levels of Byetta (exenatide). The patch, in a 12- and a 24-hour form, will use the company's proprietary PassPort Transdermal Delivery System. Lilly and Amylin will fund all development, manufacturing, and marketing activities for the product. 

comments 2 comments - Apr 7, 2009 - * * * * *

FDA Poised to Review Two New Drugs for Type 2 Diabetes

The FDA has announced that starting in early April, its Endocrinologic and Metabolic Drugs Advisory Committee will begin looking into two new drugs for type 2 diabetes: saxagliptin tablets from Bristol-Meyers Squibb and liraglutide, an injection drug from Novo Nordisk.

comments 1 comment - Mar 24, 2009 - * * * * *

FDA Unlikely to Approve Byetta Monotherapy Soon
FDA Unlikely to Approve Byetta Monotherapy Soon

Hopes that the U.S. Food and Drug Administration would move soon to make the diabetes drug Byetta a monotherapy are fading. It now appears that the FDA will extend its review of the drug into 2009.

comments 5 comments - Dec 15, 2008 - * * *

ADVERTISEMENT